AI Terminal
VERICI DX PLC
Share Issue/Capital Change • Jun 20, 2022
8005_rns_2022-06-20_da385868-4870-42a3-ae75-38550a4c34fc.html
Share Issue/Capital Change
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 4368P
Verici Dx PLC
20 June 2022
Verici Dx plc
("Verici Dx" or the "Company")
Distribution of Verici Dx shares by EKF Diagnostics Holdings plc
Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, notes the announcement made by EKF Diagnostics Holdings PLC ("EKF") this morning (RNS 3845P), declaring the distribution of its Verici Dx Investment Shares to Relevant EKF Shareholders via a distribution in specie.
These shares comprise of 9,098,611 ordinary shares in Verici Dx of £0.001 each and are subject to a Lock-up Period of 365 days from transfer.
Full details can be seen in the EKF announcement here:
Capitalised terms in this announcement carry the same definitions as in the EKF announcement.
Enquiries:
| Verici Dx | www.vericidx.com |
| Sara Barrington, CEO | Via Walbrook PR |
| Julian Baines, Chairman | |
| Singer Capital Markets (Nominated Adviser & Broker) | Tel: 020 7496 3000 |
| Aubrey Powell / Kailey Aliyar / Rachel Hayes | |
| Walbrook PR Limited | Tel: 020 7933 8780 or [email protected] |
| Paul McManus / Sam Allen | Mob: 07980 541 893 / 07502 558 258 |
About Verici Dx plc www.vericidx.com
Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology and collaboration with medical device, biopharmaceutical and data science partners.
The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCBKKBKABKKOAB